Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience
暂无分享,去创建一个
U. Mansmann | N. Harbeck | O. Gluz | R. Issels | O. Stoetzer | L. Lindner | S. Abdel-Rahman | C. Salat | M. Hamann | M. Braun | D. Di Gioia | F. Edler von Koch | R. Würstlein
[1] S. Loi,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.
[2] F. Feuerhake,et al. Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial , 2019, General Session Abstracts.
[3] W. Eiermann,et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.
[4] S. Sleijfer,et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. , 2018, Clinics in oncology.
[5] N. Harbeck,et al. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results , 2018, Journal of the National Cancer Institute.
[6] Peter Wust,et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial , 2018, JAMA oncology.
[7] P. Fasching,et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.
[8] N. Harbeck,et al. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. , 2017, Breast.
[9] Sung-Bae Kim,et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.
[10] C. Diederich,et al. Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements , 2017, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[11] W. Hiddemann,et al. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair , 2016, International journal of cancer.
[12] R. Issels,et al. Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application , 2016, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[13] H. Iwata,et al. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG , 2015, Breast Cancer.
[14] N. Harbeck,et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. , 2015 .
[15] J. Ragaz,et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.
[16] Brigitte Rack,et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Jung Sun Kim,et al. Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients , 2014, Journal of breast cancer.
[18] U. Mansmann,et al. Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter Study , 2014, Annals of surgery.
[19] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[20] M. Rezai,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[21] J. Stap,et al. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies , 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[22] Roland Wunderlich,et al. Old and new facts about hyperthermia-induced modulations of the immune system , 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[23] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Kanaar,et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition , 2011, Proceedings of the National Academy of Sciences.
[25] M. Dewhirst,et al. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] Peter Wust,et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.
[27] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] G. Raaphorst,et al. Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair. , 2005, Oncology reports.
[29] Zeljko Vujaskovic,et al. Randomized trial of hyperthermia and radiation for superficial tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W Budach,et al. Thermoradiotherapy of the chest wall in locally advanced or recurrent breast cancer with marginal resection , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[31] N. Uzunoglu,et al. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] D. Jäger,et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. , 2001, European Journal of Cancer.
[33] D Machin,et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. , 1996, International journal of radiation oncology, biology, physics.
[34] C. Ng,et al. A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment , 1996, Cancer Chemotherapy and Pharmacology.
[35] M. Kaufmann,et al. Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .
[36] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] H. Junkermann,et al. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. , 1994, Geburtshilfe und Frauenheilkunde.